LON:SNG Synairgen (SNG) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Synairgen Stock (LON:SNG) Get Synairgen alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.85 million shsAverage Volume1.63 million shsMarket Capitalization£9.04 millionP/E RatioN/ADividend Yield1.53%Price TargetN/AConsensus RatingN/A Company Overview Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com Read More Receive SNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNG Stock News HeadlinesFirst patient dosed in Synairgen’s global phase 2 INVENT studyDecember 8, 2025 | investing.comSynairgen Shares Plunge on AIM Delisting ProposalMarch 12, 2025 | marketwatch.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 2 at 1:00 AM | Paradigm Press (Ad)Synairgen shares tumble over 23% after AIM delisting plansMarch 12, 2025 | finance.yahoo.comSynairgen Secures £18 Million Funding Amidst AIM Delisting PlansJanuary 16, 2025 | tipranks.comSynairgen Leads The Charge With 2 Other Promising Penny Stocks On UK ExchangeDecember 11, 2024 | uk.finance.yahoo.comBioventix PLC (BVXP.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comSynairgen Share Chat (SNG)September 17, 2024 | lse.co.ukSee More Headlines SNG Stock Analysis - Frequently Asked Questions How were Synairgen's earnings last quarter? Synairgen plc (LON:SNG) announced its quarterly earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share for the quarter. How do I buy shares of Synairgen? Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Synairgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN). Company Calendar Last Earnings9/29/2020Today9/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:SNG CIKN/A Webwww.synairgen.com Phone+44-23-80512800FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£15.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.06% Return on Assets-30.58% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio6.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow1.90 Book ValueGBX 4.75 per share Price / BookN/AMiscellaneous Outstanding Shares977,714,692Free FloatN/AMarket Cap£9.04 million OptionableNot Optionable Beta-2.23 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:SNG) was last updated on 9/2/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | Sponsored#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being calle...Stansberry Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synairgen plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Synairgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
